Adjusted net profit stood at Rs 2,792.38 crore, down 10.44% year on year from Rs 3,117.95 crore. Sequentially, adjusted net profit declined 8.14% from Rs 3,039.73 crore.
EBITDA increased 4.8% year on year to Rs 4,743.9 crore, while EBITDA margin stood at 29.3%. Research and development investment was Rs 778.4 crore, equivalent to 4.8% of sales.
Profit before tax stood at Rs 3,159.37 crore in Q2 FY27, down 22.92% vs previous quarter and 24.19% vs year-ago quarter.
Total expenditure increased 14.35% year on year to Rs 12,213.16 crore from Rs 10,680.76 crore. Raw material consumption rose 43% to Rs 2,318.70 crore, while employee expenses increased 18.42% to Rs 3,274.16 crore. Interest costs declined 25.23% to Rs 74.67 crore, while depreciation and amortisation increased 3.95% to Rs 758.34 crore.
India formulation sales increased 17.3% year on year to Rs 5,552.3 crore, accounting for 34.5% of consolidated sales. US formulation sales declined 8.2% to US$455 million. Emerging Markets formulation sales grew 7.6% to US$350 million, while Rest of World sales increased 3.1% to US$241 million.
Global Innovative Medicines sales rose 6.9% year on year to US$356 million, contributing 21.1% of consolidated sales. API external sales increased 13.7% YoY to Rs 488.9 crore in Q2 FY27.
Managing director Kirti Ganorkar said quarterly performance was supported by strong momentum in India, Emerging Markets and Rest of World. He highlighted the US approval of Ilumya for adults with active psoriatic arthritis and the licensing of lerodalcibep, a PCSK9 inhibitor, for markets outside the US and China.
The company said integration planning for the Organon acquisition was progressing as scheduled, with regulatory approvals secured in most regions and the remaining approvals tracking as planned.
On 27 April 2026, the group entered into a definitive agreement to acquire all outstanding shares of Organon & Co. for US$14 per share in an all-cash transaction, valuing the enterprise at US$11.75 billion. The acquisition remains subject to regulatory approvals and other closing conditions.
Sun Pharmaceutical Industries is a global pharmaceutical company with businesses across innovative medicines, generics and consumer healthcare. It is India's largest pharmaceutical company and has a presence in the US and emerging markets. Its innovative medicines portfolio focuses on dermatology, ophthalmology and onco-dermatology, contributing about 22% of sales. The company operates manufacturing facilities across five continents and supplies medicines to customers in over 100 countries.
Shares of Sun Pharmaceutical Industries rose 0.95% to settle at Rs 1,777.70 on 30 October 2026.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."